Inozyme Pharma Files 8-K with Material Agreement Details
| Field | Detail |
|---|---|
| Company | Inozyme Pharma, Inc. |
| Form Type | 8-K |
| Filed Date | May 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, corporate-update
Related Tickers: INZY
TL;DR
INOZOME PHARMA (INZY) FILED AN 8-K ON 5/16/25 - MATERIAL AGREEMENT DETAILS INSIDE.
AI Summary
On May 16, 2025, Inozyme Pharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 321 Summer Street, Suite 400, Boston, MA.
Why It Matters
This filing indicates a significant new contract or partnership for Inozyme Pharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood by the market.
Key Numbers
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
Key Players & Entities
- Inozyme Pharma, Inc. (company) — Registrant
- May 16, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 321 Summer Street, Suite 400, Boston, Massachusetts 02210 (address) — Principal Executive Offices
- 001-39397 (identifier) — Commission File Number
FAQ
What is the nature of the material definitive agreement filed by Inozyme Pharma?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the summary information of the 8-K.
When was this 8-K report filed?
The report was filed on May 16, 2025.
What is Inozyme Pharma's primary business classification?
Inozyme Pharma, Inc. is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Where are Inozyme Pharma's principal executive offices located?
The company's principal executive offices are located at 321 Summer Street, Suite 400, Boston, Massachusetts 02210.
What is the Commission File Number for Inozyme Pharma?
The Commission File Number for Inozyme Pharma, Inc. is 001-39397.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 16, 2025 regarding Inozyme Pharma, Inc..